Epigenetic Mechanisms in Neuroendocrine Neoplasms: Is There a Place for Inhibitors of DNA Binding Proteins?
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl26581 ↗At a glance
Übersichtsarbeit in Frontiers in Bioscience-Landmark, 2025. Written by David Sanchis-Pascual and 5 co-authors. Institution: Endocrinology and Nutrition Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain. Major MEDLINE topics: Epigenesis, Genetic, Neuroendocrine Tumors, DNA-Binding Proteins, Inhibitor of Differentiation Proteins. Cited 1 times so far (Crossref); 168 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Inhibitors of DNA-binding (Id) proteins constitute a family of repressor factors that modulate a multitude of cellular processes and have been linked to tumor aggressiveness, resistance to chemotherapy, angiogenesis, and worse prognosis in numerous malignancies. This review explores the role of Id proteins in the pathogenesis of neuroendocrine neoplasms (NENs). The findings revealed that this family of proteins shows significant overexpression in tumors such as small cell lung carcinoma (SCLC), neuroendocrine prostate carcinoma (NEPC), and medullary thyroid carcinoma (MTC), although the role of epigenetics in regulating Id proteins within NENs remains poorly understood, with most evidence limited to NEPC. These results underscore the potential of Id proteins not only as diagnostic biomarkers and promising therapeutic targets for the management of NENs, but also highlight the need for further research to better understand their epigenetic regulation and broader role in these tumors.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Endocrinology and Nutrition Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain.
- Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, Health Research Institute La Fe, 46026 Valencia, Spain.
- Pediatric Endocrinology Unit, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain.
- Nuclear Medicine Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain.
- Medical Oncology Department, University and Politecnic Hospital La Fe (Valencia), 46026 Valencia, Spain.
- Department of Medicine, University of Valencia, 46010 Valencia, Spain.
Cite
APA
Sanchis-Pascual, D., Olmo-García, M. I. D., Morillas-Amat, P., Prado-Wohlwend, S., Segura Huerta, Á., & Merino-Torres, J. F. (2025). Epigenetic Mechanisms in Neuroendocrine Neoplasms: Is There a Place for Inhibitors of DNA Binding Proteins?. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl26581
Vancouver
Sanchis-Pascual D, Olmo-García MID, Morillas-Amat P, Prado-Wohlwend S, Segura Huerta Á, Merino-Torres JF. Epigenetic Mechanisms in Neuroendocrine Neoplasms: Is There a Place for Inhibitors of DNA Binding Proteins?. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl26581
BibTeX
@article{SanchisPascual2025,
author = {Sanchis-Pascual, David and Olmo-García, María Isabel Del and Morillas-Amat, Pilar and Prado-Wohlwend, Stefan and Segura Huerta, Ángel and Merino-Torres, Juan Francisco},
title = {Epigenetic Mechanisms in Neuroendocrine Neoplasms: Is There a Place for Inhibitors of DNA Binding Proteins?},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl26581}
}
EUVIMED